Head to Head Comparison: Revelation Biosciences (NASDAQ:REVB) and Vincerx Pharma (NASDAQ:VINC)

Revelation Biosciences (NASDAQ:REVB) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability and dividends.

Profitability

This table compares Revelation Biosciences and Vincerx Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Revelation Biosciences	N/A	-84.25%	-51.31%
Vincerx Pharma	N/A	-187.73%	-126.26%

Insider and Institutional Ownership

12.8% of Revelation Biosciences shares are held by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are held by institutional investors. 1.4% of Revelation Biosciences shares are held by company insiders. Comparatively, 20.6% of Vincerx Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Revelation Biosciences has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Comparatively, Vincerx Pharma has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Revelation Biosciences and Vincerx Pharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revelation Biosciences	0	0	0	0	N/A
Vincerx Pharma	0	0	1	0	3.00

Vincerx Pharma has a consensus target price of $5.00, suggesting a potential upside of 488.24%. Given Vincerx Pharma’s higher probable upside, analysts clearly believe Vincerx Pharma is more favorable than Revelation Biosciences.

Valuation & Earnings

This table compares Revelation Biosciences and Vincerx Pharma’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revelation Biosciences	N/A	N/A	-$120,000.00	$30.41	0.07
Vincerx Pharma	N/A	N/A	-$40.16 million	($1.89)	-0.45

Vincerx Pharma is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

About Revelation Biosciences

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, urinary tract infection, sepsis, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease. It is also developing REVTx-99b, a treatment for food allergies; REVTx-99a, an anti-viral nasal drop solution for the potential prevention or treatment of respiratory viral infection; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, influenza A, influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.

About Vincerx Pharma

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.